Expand ZLAB Menu
ZLAB MENU

ZLAB Latest Press Releases

-- June 16, 2026 --

Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas Business Wire 7:00 AM

-- June 8, 2026 --

Zai Lab Receives China NMPA Approval of TIVDAK (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer Business Wire 8:34 PM

-- May 21, 2026 --

Zai Lab Announces Changes to Senior Leadership Team Business Wire 6:09 PM

-- May 11, 2026 --

Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs) Business Wire 7:00 AM

-- May 7, 2026 --

Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates Business Wire 6:00 AM

-- April 22, 2026 --

Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026 Business Wire 7:30 AM

-- April 18, 2026 --

Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Ra Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases Business Wire 9:00 AM

-- April 17, 2026 --

Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas Business Wire 3:01 PM

-- April 15, 2026 --

Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3-targeting T-Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas Globe Newswire 8:00 AM

-- April 1, 2026 --

Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy Business Wire 7:30 AM

-- March 17, 2026 --

Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC) Business Wire 4:35 PM

-- February 26, 2026 --

Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates Business Wire 7:00 AM

-- February 10, 2026 --

Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026 Business Wire 8:30 AM
Market Data Delayed 15 Minutes